Powered by:                              

About the digital event

On Monday, March 23 — on the eve of World Tuberculosis Day — Devex and USP will host a digital Newsmaker event to discuss TB efforts, and how in the era of COVID-19, progress can still be made.

Tuberculosis remains the world’s deadliest infectious killer, with a range of devastating health, social and economic consequences. According to the World Health Organization, each day more than 4,000 people lose their lives to TB and close to 30,000 people fall ill with this preventable and curable disease.

A global effort to combat TB has saved an estimated 58 million lives since the year 2000, but how can international development actors help accelerate the TB response and ensure access to care, especially as the global health community drives towards universal health coverage?

We will assess the pace of progress following September 2018's first-ever U.N. High Level Meeting on TB; find out how we can accelerate the urgency of in-country responses; dive deeper into how to ensure sustainable financing to power an effective response; and discuss how the global development community can help scale up access to prevention and treatment. 







Join the online conversation using #EndTB and #DevexNewsmaker, as well as tagging @Devex and @USPharmacopeia.

Register on this page for the link to join by laptop, tablet or mobile device. We invite you to share your questions with us in advance to [email protected] — or submit them to our speakers during the event using the live Q&A chat box.
Can't make it?
Register anyway and we'll send you a recorded version of the session.

The Speakers

Moderator

Adva Saldinger

Associate Editor & Senior Reporter
Devex
As a senior reporter based in Washington, D.C., Adva leads coverage of the intersection between business and global development. For the latest on innovative finance, private sector engagement and entrepreneurship follow her reporting. A business journalist with more than 10 years of experience, she worked at several newspapers in the U.S. and lived in both Ghana and South Africa. Adva grew up in California, where she developed a great love of nature and the outdoors.

Dr. Lucica Ditiu

Executive Director
Stop TB Partnership

Dr. Lucica Ditiu is the Executive Director of the Stop TB Partnership since May 2011.

Lucica Ditiu is a Romanian physician and public health expert who has devoted her career to helping and supporting people affected by TB, especially those most vulnerable, most stigmatized and living in impoverished communities.

Lucica Ditiu has led the Stop TB Partnership for the last 8 years. Under her leadership, the organization has gained a clear identity and evolved into a lean, innovative and progressive team that represents one of the most influential advocacy voices on global health and tuberculosis, providing support - financial as well as TB medicines and diagnostics – for a TB response towards a world without TB. A firm believer in innovation, flexibility and change, Dr. Ditiu is relentless in pushing for the inclusion of all people affected by TB, with an ambitious agenda of transparency and accountability that continuously challenges the status quo.

Dr. Susan Maloney

CDC Global TB Branch Chief
CDC

Dr. Susan Maloney is the Chief of the Global Tuberculosis Branch, Division of Global HIV and TB, at the US Centers for Disease Control and Prevention, responsible for overseeing CDC’s Global TB portfolio and strengthening programmatic and research collaborations to increase impact on global TB diagnosis, care and prevention efforts.

Prior to taking on her role in Global TB, Dr. Maloney  was the Director of CDC’s Southeast Asia Regional Global Disease Detection Center and International Emerging Infections Program (located in Thailand), and worked with national and regional partners and WHO to strengthen surveillance, laboratory, research and response capacities for emerging and re-emerging diseases. During her tenure at CDC, Dr. Maloney also served as the Chief of the Immigrant, Refugee and Migrant Health Branch, where she led investigations of infectious disease outbreaks among migrating populations, and implemented a research agenda evaluating the effectiveness of medical screening for U.S.-bound refugees and immigrants, which resulted in a change in U.S. policies for overseas TB diagnosis and treatment, and a substantial increase in the diagnosis and treatment of TB among these populations.  

Ronald T. Piervincenzi, Ph.D

Chief Executive Officer
USP
Ronald T. Piervincenzi, Ph.D., has served as Chief Executive Officer of the United States Pharmacopeia since February 2014. Dr. Piervincenzi provides strategic leadership to USP’s global staff of over 1,400 across sites in Rockville/USA, Brazil, China, Ghana, and India. His transformative vision has launched key USP initiatives in bringing quality across the healthcare spectrum, upholding USP’s reputation as a quality leader since its founding in 1820. Under his leadership, USP has modernized its operations and launched innovative new science, including in the areas of digital medicine, cutting-edge manufacturing technologies and advanced biologics. USP is also better connecting to its stakeholders and customers through new initiatives including the Hyderabad Training Institute in India, the Quality Institute, and USP’s new Impurities for Development service. Dr. Piervincenzi also provides oversight and leadership of USP’s global public health initiatives, including sites in Ethiopia, Indonesia, Nigeria and the Philippines. Dr. Piervincenzi served as Chair of the Council of Experts, USP's scientific standards-setting body of 24 Expert Committees and over 750 standards-setting experts until June 2015, when he transferred this responsibility to USP’s new Chief Science Officer.

Raj Kumar

President and Editor-in-Chief
Devex
Raj Kumar is the Founding President and Editor-in-Chief at Devex, the media platform for the global development community. He is a media leader and former humanitarian council chair for the World Economic Forum and a member of the Council on Foreign Relations. His work has led him to more than 50 countries, where he has had the honor to meet many of the aid workers and development professionals who make up the Devex community. He is the author of the book "The Business of Changing the World," a go-to primer on the ideas, people, and technology disrupting the aid industry.

Office Cat

Mouse Catcher
Quarantine land
And both of these, if one would tell the truth, were foreordained unto the holy place, where greatest Peter’s follower hath his seat. While on this quest, for which thou giv’st him praise, he heard the things which of his victory the causes were, and of the Papal Robe. The Chosen Vessel went there afterward, to bring thence confirmation in the faith, through which one enters on salvation’s path. But why should I go there, or who concedes it? I ’m not Aeneas, nor yet Paul am I; me worthy of this, nor I nor others deem. If, therefore, I consent to come, I fear lest foolish be my coming; thou art wise, and canst much better judge than I can talk.”

Office Cat

Mouse Catcher
Quarantine land
And both of these, if one would tell the truth, were foreordained unto the holy place, where greatest Peter’s follower hath his seat. While on this quest, for which thou giv’st him praise, he heard the things which of his victory the causes were, and of the Papal Robe. The Chosen Vessel went there afterward, to bring thence confirmation in the faith, through which one enters on salvation’s path. But why should I go there, or who concedes it? I ’m not Aeneas, nor yet Paul am I; me worthy of this, nor I nor others deem. If, therefore, I consent to come, I fear lest foolish be my coming; thou art wise, and canst much better judge than I can talk.”
Share your thought leadership with our community. Partner with Devex LIVE on an event.
Start the conversation